<DOC>
	<DOCNO>NCT00407550</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving pemetrexed disodium together gemcitabine may kill tumor cell . PURPOSE : This randomized phase II trial study two different schedule pemetrexed disodium gemcitabine compare well work treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Disodium Gemcitabine Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare response rate patient stage IIIB IV non-small cell lung cancer treat two different treatment schedule pemetrexed disodium gemcitabine hydrochloride . Secondary - Compare time-to-event efficacy variable patient treat regimen . - Compare progression-free overall survival patient treat regimen . - Determine overall toxicity regimens patient . OUTLINE : This multicenter , open-label , randomize study . Patients stratify accord disease stage ( IIIB v IV ) ECOG performance status ( 0 vs 1 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive pemetrexed disodium IV 10 minute gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive pemetrexed disodium IV 10 minute gemcitabine hydrochloride IV 30 minute day 1 . Treatment repeat every 14 day 9 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 80 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB ( control pleural effusion ) OR stage IV disease At least 1 measurable lesion whose long diameter ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No medically significant thirdspace fluid collection ( e.g. , ascites pleural effusion ) control drainage procedures No documented brain metastasis unless follow criterion meet : Successful local therapy complete At least 2 week since prior corticosteroid Brain imaging require symptomatic patient ( rule brain metastasis ) Concurrent enrollment clinical trial MCCRCRC0527 require PATIENT CHARACTERISTICS : Life expectancy ≥ 12 week ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN AST ALT ≤ 3 time ULN ( 5 time ULN liver involvement ) Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able take folic acid , cyanocobalamin ( vitamin B12 ) supplementation , dexamethasone corticosteroid Able interrupt intake aspirin nonsteroidal antiinflammatory agent total 5 day No severe and/or uncontrolled medical condition , include follow : Hypertension , labile hypertension , history poor compliance antihypertensive medication Angina pectoris Congestive heart failure within past 3 month , unless ejection fraction &gt; 40 % Myocardial infarction within past 6 month Cardiac arrhythmia Diabetes Interstitial pneumonia extensive symptomatic interstitial fibrosis lung New York Heart Association class III IV heart disease Clinically significant infection No serious medical condition illness would preclude study participation No peripheral neuropathy ≥ grade 2 No malignancy within past 5 year except nonmelanomatous skin cancer , carcinoma situ cervix , lowgrade ( Gleason score ≤ 6 ) localize prostate cancer No significant weight loss ( ≥ 10 % ) within past 6 week No investigator site personnel directly affiliate study , immediate family ( i.e. , spouse , parent , child , sibling , whether biological legally adopt ) No employee Eli Lilly ( i.e. , employee , temporary contract worker , designees responsible conduct study ) Immediate family Eli Lilly employee may participate Eli Lillysponsored clinical trial , permit participate Eli Lilly facility PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior corticosteroid At least 4 week since prior radiation therapy involve &gt; 25 % bone marrow recover At least 30 day since prior investigational therapy No prior radiation therapy whole pelvis No prior systemic chemotherapy advance nonsmall cell lung cancer No prior pemetrexed disodium and/or gemcitabine hydrochloride No prior concurrent sorafenib tosylate and/or temsirolimus No concurrent Hypericum perforatum ( St. John 's wort ) No concurrent antitumor therapy No concurrent agent stimulate thrombopoiesis Concurrent palliative radiation therapy allow Concurrent corticosteroid allow adrenal insufficiency severe nausea vomit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>